Darko Miljkovic MSc, PhD

Darko Miljkovic MSc, PhD has extensive experience in the pharmaceutical industry, with a focus on medical affairs and oncology. Darko is currently working as the Vice President of Global Medical Affairs Hematology at Stemline Therapeutics since 2023. Prior to that, Darko worked at GSK from 2020 to 2023 as the Europe Medical Lead Hematology and Cell & Gene pipeline. Their responsibilities at GSK included medical strategy and planning, cross-functional collaboration, launch execution, and implementation of real-world evidence strategies.

Before joining GSK, Darko worked at AbbVie from 2017 to 2020 as the Medical Lead for CLL and Solid Tumors in Western Europe & Canada. During their time at AbbVie, they played a key role in driving medical affairs activities, launch preparations, and supporting clinical trial programs.

From 2014 to 2017, Darko served as the Medical Head of Hematology, Emerging Growth Markets at Novartis. Darko was responsible for regional medical strategy and staff management in the Leukemia Franchise, Multiple Myeloma, and CLL.

Darko also gained experience at other companies, including Bristol-Myers Squibb, Celgene, Boehringer Ingelheim, and Servier. At Boehringer Ingelheim, they held the position of Medical Affairs Manager for Cardiovascular/Thrombosis and made significant contributions in scientific and medical input, staff management, international collaborative projects, and KOL communication.

Throughout their career, Darko has demonstrated expertise in medical affairs, strategic planning, cross-functional collaboration, launch preparations, clinical trial support, real-world evidence implementation, staff management, and KOL engagement.

Darko Miljkovic MSc, PhD has a diverse education history in the field of clinical epidemiology and related areas. Darko started their educational journey at CY Cergy Paris Université in 2003, where they pursued a MsC degree in Organic Chemistry. In the same year, they also obtained a University Diploma in Clinical Trials from Clinsearch.

Miljkovic then continued their studies at Pierre and Marie Curie University from 2005 to 2007, during which they earned a postgraduate degree in Public Health, Clinical Epidemiology. This provided him with a solid foundation in the field.

Moving forward, they pursued further specialization in Clinical Hematology at Pierre and Marie Curie University from 2010 to 2011, obtaining a postgraduate degree in the subject.

In 2012, Miljkovic attended Institut Gustave Roussy, Paris for a clinical course on antitumoral chemotherapy, where they completed a postgraduate certificate program.

Finally, Miljkovic completed their formal education by pursuing a PhD at Université Henri Poincaré, Nancy 1 from 2008 to 2013. Their research and studies during this period focused on Clinical Epidemiology, providing him with advanced knowledge and expertise in the field.

Overall, Darko Miljkovic MSc, PhD possesses a comprehensive education history, with a strong emphasis on clinical epidemiology and related areas.